Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Fri., Apr. 19, 2:18 AM
Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.
Slide #46. Forest Laboratories — Aptalis
Acquirer: |
Forest Laboratories (FRX) |
Acquiree: |
Aptalis |
Details: |
Forest Laboratories, Inc. announced that it has entered into a definitive agreement to acquire Aptalis, a privately held U.S. based specialty Gastrointestinal (GI) and Cystic Fibrosis company, for $2.9 billion in cash from its shareholders, including TPG, the global private investment firm. The acquisition, which requires review by anti-trust authorities in the US and Canada, is expected to be accretive to Forest's FY2015 non-GAAP EPS. |
Forest Road is a blank check company whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
Open the FRX Page at The Online Investor »
Open the FRX Page at The Online Investor (in a new window) »
|
April 19, 2024 2:18 AM Eastern
Hold (2.47 out of 4)
100th percentile
|
|